|
1
|
Ljungberg B, Campbell SC, Cho HY, Jacqmin
D, Lee JE, Weikert S and Kiemeney LA: The epidemiology of renal
cell carcinoma. Eur Urol. 60:615–621. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gupta K, Miller JD, Li JZ, Russell MW and
Charbonneau C: Epidemiologic and socioeconomic burden of metastatic
renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev.
34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Du YJ, Pahernik S, Hadaschik B, Teber D,
Duensing S, Jäger D, Hohenfellner M and Grüllich C: Survival and
prognostic factors of patients with renal cell cancer with bone
metastasis in the era of targeted therapy: A single-institution
analysis. Urol Oncol. 34:433.e1–e8. 2016. View Article : Google Scholar
|
|
4
|
Bianchi M, Sun M, Jeldres C, Shariat SF,
Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P,
et al: Distribution of metastatic sites in renal cell carcinoma: A
population-based analysis. Ann Oncol. 23:973–980. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Santini D, Procopio G, Porta C, Ibrahim T,
Barni S, Mazzara C, Fontana A, Berruti A, Berardi R, Vincenzi B, et
al: Natural history of malignant bone disease in renal cancer:
Final results of an Italian bone metastasis survey. PLoS One.
8:e830262013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kinnane N: Burden of bone disease. Eur J
Oncol Nurs (11 Suppl 2). S28–S31. 2007. View Article : Google Scholar
|
|
7
|
Mirels H: Metastatic disease in long
bones: A proposed scoring system for diagnosing impending
pathologic fractures. 1989. Clin Orthop Relat Res. (415
Suppl):S4–S13. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ruppert LM: Malignant spinal cord
compression: Adapting conventional rehabilitation approaches. Phys
Med Rehabil Clin N Am. 28:101–114. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Umer M, Mohib Y, Atif M and Nazim M:
Skeletal metastasis in renal cell carcinoma: A review. Ann Med Surg
(Lond). 27:9–16. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Taunk NK, Spratt DE, Bilsky M and Yamada
Y: Spine radiosurgery in the management of renal cell carcinoma
metastases. J Natl Compr Cancer Netw. 13:801–809. 2015. View Article : Google Scholar
|
|
11
|
Motzer RJ, Hutson TE, Cella D, Reeves J,
Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, et
al: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
N Engl J Med. 369:722–731. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson D, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C,
Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus everolimus in advanced
renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Motzer RJ, Tannir NM, McDermott DF, Arén
Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P,
Porta C, George S, et al: Nivolumab plus ipilimumab versus
sunitinib in advanced renal-cell carcinoma. N Engl J Med.
378:1277–1290. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Woolf DK, Padhani AR and Makris A:
Assessing response to treatment of bone metastases from breast
cancer: What should be the standard of care? Ann Oncol.
26:1048–1057. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hamaoka T, Madewell JE, Podoloff DA,
Hortobagyi GN and Ueno NT: Bone imaging in metastatic breast
cancer. J Clin Oncol. 22:2942–2953. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McKay RR, Bossé D, Gray KP, Michaelson MD,
Krajewski K, Jacene HA, Walsh M, Bellmunt J, Pomerantz M, Harshman
LC and Choueiri TK: Radium-223 dichloride in combination with
vascular endothelial growth factor-targeting therapy in advanced
renal cell carcinoma with bone metastases. Clin Cancer Res.
24:4081–4088. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jehn CF, Diel IJ, Overkamp F, Kurth A,
Schaefer R, Miller K and Lüftner D: Management of metastatic bone
disease algorithms for diagnostics and treatment. Anticancer Res.
36:2631–2637. 2016.PubMed/NCBI
|
|
20
|
Motzer RJ, Escudier B, Bukowski R, Rini
BI, Hutson TE, Barrios CH, Lin X, Fly K, Matczak E and Gore ME:
Prognostic factors for survival in 1059 patients treated with
sunitinib for metastatic renal cell carcinoma. Br J Cancer.
108:2470–2477. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Motzer RJ, Escudier B, Oudard S, Hutson
TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA,
Hollaender N, et al: Phase 3 trial of everolimus for metastatic
renal cell carcinoma: Final results and analysis of prognostic
factors. Cancer. 116:4256–4265. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kitamura H, Takahashi A, Takei F, Hotta H,
Miyano N, Shindo T, Igarashi M, Tachiki H, Kunishima Y, Muranaka T,
et al: Molecular-targeted therapy and surgery may prolong survival
of renal cell carcinoma patients with bone metastasis: A
multi-institutional retrospective study in Japan. Anticancer Res.
36:5531–5536. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ruatta F, Derosa L, Escudier B, Colomba E,
Guida A, Baciarello G, Loriot Y, Fizazi K and Albiges L: Prognosis
of renal cell carcinoma with bone metastases: Experience from a
large cancer centre. Eur J Cancer. 107:79–85. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zekri J, Ahmed N, Coleman RE and Hancock
BW: The skeletal metastatic complications of renal cell carcinoma.
Int J Oncol. 19:379–382. 2001.PubMed/NCBI
|
|
25
|
Choueiri TK, Escudier B, Powles T, Tannir
NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola
K, et al: Cabozantinib versus everolimus in advanced renal cell
carcinoma (METEOR): Final results from a randomised, open-label,
phase 3 trial. Lancet Oncol. 17:917–927. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Morris ZS and Harari PM: Interaction of
radiation therapy with molecular targeted agents. J Clin Oncol.
32:2886–2893. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sharabi AB, Lim M, DeWeese TL and Drake
CG: Radiation and checkpoint blockade immunotherapy:
Radiosensitisation and potential mechanisms of synergy. Lancet
Oncol. 16:e498–e509. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tokuhashi Y, Matsuzaki H, Oda H, Oshima M
and Ryu J: A revised scoring system for preoperative evaluation of
metastatic spine tumor prognosis. Spine (Phila Pa 1976).
30:2186–2191. 2005. View Article : Google Scholar : PubMed/NCBI
|
